Press-release for stocks for lly

symbols : Lly

save search

Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Published: 2022-07-12 (Crawled : 21:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 124.45% | O: -0.49% H: 0.83% C: 0.14%
VERU | $1.305 -8.1% -8.81% 2.6M

Health Technology

| -91.27% | O: -2.0% H: 14.15% C: 8.44%
nasdaq grants

Global Osteoporosis Treatment Market to Surpass US$ 18.92 Billion by 2030 - Coherent Market Insights
Published: 2022-07-12 (Crawled : 18:00) - prnewswire.com
VTRS A | $11.25 1.17% 1.16% 4.7M

Health Technology

| 11.94% | O: -0.4% H: 3.2% C: 2.1%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| 11.68% | O: -0.13% H: 0.14% C: -0.52%
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 119.38% | O: -0.32% H: 0.6% C: -1.94%
NNOX | $8.62 -4.96% -5.22% 1M

Health Technology

| -28.03% | O: -0.5% H: 5.47% C: 3.62%
LGND | $72.59 0.1% 0.1% 140K

Health Technology

| -21.96% | O: -0.3% H: 3.16% C: 2.67%
AMGN | $269.03 2.39% 2.33% 3.4M

Health Technology

| 8.54% | O: 0.0% H: 0.93% C: -0.33%
treatment market osteoporosis

Plaque Psoriasis Market to Advance Upto USD 25 Billion by 2032 | DelveInsight
Published: 2022-07-12 (Crawled : 16:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -16.7% | O: 0.3% H: 0.0% C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 119.38% | O: -0.32% H: 0.6% C: -1.94%
psoriasis market plague

$7.9 Billion Worldwide Human Growth Hormone Industry to 2027 - Featuring Genentech, Ipsen, Merck and Novartis Among Others
Published: 2022-07-11 (Crawled : 17:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| 11.88% | O: -0.04% H: 0.65% C: 0.21%
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 119.78% | O: 0.04% H: 0.63% C: 0.14%
novartis growth hormone

Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
Published: 2022-05-10 (Crawled : 15:20) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 151.12% | O: 0.93% H: 0.0% C: 0.0%
ACRS | $1.25 1.63% 1.6% 580K

Health Technology

| -88.88% | O: 4.22% H: 1.98% C: -4.3%
therapeutics update results

Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients
Published: 2022-07-06 (Crawled : 12:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 125.53% | O: 1.85% H: 1.45% C: 0.66%
VERU | $1.305 -8.1% -8.81% 2.6M

Health Technology

| -88.63% | O: 0.26% H: 20.43% C: 12.73%
covid-19 treatment sabizabulin trial results publication phase 3

With Market Size Valued at $13.7 Billion by 2026, it`s a Healthy Outlook for the Global Angina Pectoris Drugs Market
Published: 2022-07-04 (Crawled : 09:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| Email alert Add to watchlist
GILD | $66.77 0.92% 0.91% 11M

Health Technology

| Email alert Add to watchlist
NVSEF | $93.6375 6.88% 82K

Health Technology

| Email alert Add to watchlist
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| Email alert Add to watchlist
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| Email alert Add to watchlist
GLAXF | News | $20.2 -14.18% 510

Health Technology

| Email alert Add to watchlist
GSK | News | $39.75 1.22% 0.0% 1.6M

Health Technology

| Email alert Add to watchlist
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| Email alert Add to watchlist
PFE A | $26.0 2.4% -0.15% 38M

Health Technology

| Email alert Add to watchlist
market

Innovent Announces First Patient Dosed in a Phase 2 Clinical study of IBI112 (IL-23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Active Ulcerative Colitis
Published: 2022-07-04 (Crawled : 01:00) - prnewswire.com
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| Email alert Add to watchlist
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| Email alert Add to watchlist
ibi112 active study phase 2 ulcerative colitis

Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options
Published: 2022-06-29 (Crawled : 11:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 122.23% | O: -2.65% H: 2.06% C: 1.52%
covid-19 treatment ongoing

Innovent Announces Phase 1b Study Results of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Published in Nature Communications
Published: 2022-06-28 (Crawled : 01:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 124.44% | O: 0.99% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -32.33% | O: -0.08% H: 0.0% C: 0.0%
ibi362 communications chinese diabetes results phase 2b

Innovent Announces Phase 1b Study Results of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Published in Nature Communications
Published: 2022-06-29 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 122.23% | O: -2.65% H: 2.06% C: 1.52%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -32.28% | O: -2.07% H: 0.58% C: 0.25%
ibi362 communications chinese diabetes results phase 2b

Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic
Published: 2022-06-28 (Crawled : 12:20) - globenewswire.com
AKYA | $3.81 -1.04% -1.05% 170K

Professional, Scientific, and T...

| -68.44% | O: 1.0% H: 4.77% C: 3.37%
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 124.44% | O: 0.99% H: 0.0% C: 0.0%
oncosignature test diagnostic therapeutics

DTx Pharma Appoints Peter Condon as Chief Business Officer
Published: 2022-06-28 (Crawled : 12:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 124.44% | O: 0.99% H: 0.0% C: 0.0%
pharma

Global Clinical Trials Markets 2022-2028: Globalization of Clinical Trials / Increasing R&D Promoting Outsourcing / Adoption of New Technology in Clinical Research
Published: 2022-06-28 (Crawled : 11:00) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M

Health Technology

| 8.97% | O: -2.98% H: 0.66% C: -0.87%
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 124.44% | O: 0.99% H: 0.0% C: 0.0%
ICLR | $288.32 -1.2% -1.21% 640K

Health Technology

| 30.49% | O: -0.57% H: 0.96% C: -0.24%
trials research technology trial

MSP Recovery Commences Billing Big Pharma More Than $5.6 Billion In Billed Amounts and More Than $2.8 Billion In Paid Amounts
Published: 2022-06-28 (Crawled : 02:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 124.44% | O: 0.99% H: 0.0% C: 0.0%
ABBV | $166.41 1.06% 0.0% 5.5M

Health Technology

| 8.71% | O: 0.06% H: 1.27% C: -0.44%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -12.16% | O: -0.27% H: 0.0% C: 0.0%
pharma

Lilly Declares Third-Quarter 2022 Dividend
Published: 2022-06-27 (Crawled : 21:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 127.41% | O: 1.32% H: 0.0% C: 0.0%

Cancer Immunotherapy Market Expands with Rising Adoption of Target Therapy in Cancer Treatment, States TMR Report
Published: 2022-06-27 (Crawled : 16:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510

Health Technology

| -23.41% | O: 0.47% H: 3.73% C: 3.73%
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -11.29% | O: 4.15% H: 0.0% C: 0.0%
AZNCF | News | $138.24 -4.19% 800

Health Technology

| 5.41% | O: -1.55% H: 4.43% C: 0.03%
PFE A | $26.0 2.4% -0.15% 38M

Health Technology

| -48.76% | O: 1.46% H: 1.45% C: 0.78%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| 12.97% | O: 1.86% H: 1.05% C: 0.24%
GSK | News | $39.75 1.22% 0.0% 1.6M

Health Technology

| -27.21% | O: -0.16% H: 0.61% C: 0.18%
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 127.41% | O: 1.32% H: 0.0% C: 0.0%
BMY | $48.93 1.3% 0.0% 10M

Health Technology

| -38.03% | O: 0.34% H: 1.72% C: 0.95%
SPPI | $1.03 -0.97% 0

Health Technology

| 17.05% | O: 0.0% H: 2.28% C: -2.27%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -11.69% | O: 0.53% H: 0.0% C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M

Health Technology

| 3.08% | O: -0.36% H: 1.22% C: 0.38%
immunotherapy report therapy cancer market treatment

Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Published: 2022-06-27 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 127.41% | O: 1.32% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -30.55% | O: 3.36% H: 0.35% C: -0.71%
tyvyt treatment approval china

AC Immune Holds Annual General Meeting of Shareholders
Published: 2022-06-24 (Crawled : 21:00) - globenewswire.com
ACIU | $2.375 -0.21% -0.21% 320K

Health Technology

| Email alert Add to watchlist
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| Email alert Add to watchlist
meeting

Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Published: 2022-06-24 (Crawled : 21:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| Email alert Add to watchlist
VERU | $1.305 -8.1% -8.81% 2.6M

Health Technology

| Email alert Add to watchlist
nasdaq grants